Table 2. Summary of Cost and Outcome Results in the Base-Case Analysis.
| Strategy | Sorafenib | Atezolizumab plus bevacizumab |
|---|---|---|
| Cost, $ | 202 973 | 292 780 |
| First-line drug | 109 355 | 214 210 |
| Other | 93 619 | 78 570 |
| Life-years | ||
| Progression-free | 0.548 | 0.938 |
| Overall | 1.736 | 3.033 |
| QALYs | 1.021 | 1.551 |
| Incremental cost per QALYa | NA | 169 223 |
| INHB, QALYa | NA | −0.068 |
| INMB, $a | NA | −10 202 |
Abbreviations: INHB, incremental net health benefit; INMB, incremental net monetary benefit; NA, not applicable; QALY, quality-adjusted life-years.
a
Compared with sorafenib.